2011 ASH Program Book - American Society of Hypertension

General Information
This program book has been underwritten by Novartis
Pharmaceuticals Corporation.
Education
Program Objectives
In keeping with the purpose of the American Society of Hypertension,
Inc. (ASH), the Twenty-Sixth Annual Scientific Meeting is designed to
encourage and promote the development, advancement, and exchange
of fair and balanced and evidence-based information regarding the
research, diagnosis and treatment of hypertension and related cardiovascular
diseases, with the goal of improved patient care and health.
The sessions will:
• Present and examine new findings on the physiology, pathophysiology,
epidemiology, diagnosis, and management of hypertension
and related conditions.
• Review current state-of-the-art advances in managing particular
groups of patients.
• Evaluate specific treatment modalities and pharmacological
agents.
Target Audience
Physicians, scientists, pharmacists, physician assistants, nurses and
other health care professionals with an interest in the mechanisms or
management of hypertension and related diseases will benefit from
attending Scientific Sessions, Satellite Symposia, Embedded Symposia,
Meet the Professor Sessions, Case Discussions, Poster Sessions and
the Scientific Exposition.
Continuing Education Credit
The American Society of Hypertension, Inc. is accredited by the
Accreditation Council for Continuing Medical Education to provide
continuing medical education for physicians. The American Society of
Hypertension, Inc. designates this educational activity for a maximum
of 30 AMA PRA Category 1 Credits. Each physician should claim
credit commensurate with the extent of their participation in the
activity.
Conflict of Interest Disclosure
The American Society of Hypertension, Inc. strives to ensure balance,
independence, objectivity, and scientific rigor in all of its educational
programs. All faculty members participating in this program have
been required to disclose any real or apparent conflict(s) of interest
that may have a direct bearing on the subject matter of the session in
which they are participating. This includes relationships in place at
the time of the meeting or in the twelve (12) months preceding the
meeting, with pharmaceutical companies, biomedical device manufacturers,
or other corporations whose products or services are related
to the subject matter of the presentation topic.
The intent of the policy is to identify openly any conflict of interest so
that the listeners may form their own judgments about the presentations
with the full disclosure of the facts. All Conflict of Interest Disclosure
Statements are available to meeting attendees in the program
book on pages 145–153 and at the ASH Information/Membership
Booth located at the entrance of the Hypertension Resource Pavilion
on the third Floor.
9